Answers are grounded in this paper and cite their sources.
-positive cases exposed to platinum chemotherapy or PARP inhibition, the prevalence of reversion mutations was 40%. This report documents the frequency of reversion mutations in a large cohort of prostate cancer patients carrying of BRCA mutations. It also shows the potential utility of ctDNA analyses for early detection of reversion mutation driving tumor resistance.
No takes yet. Share an insight, caveat, or question.
Carneiro et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: